Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Breast Cancer Congress 2022

Can we decrease chemotherapy in LN+ premenopausal women based on genomic tests?

Second vote and conclusions

Date

04 May 2022

Session

Can we decrease chemotherapy in LN+ premenopausal women based on genomic tests?

Topics

Cytotoxic Therapy

Tumour Site

Breast Cancer

Presenters

David Cameron

Authors

D. Cameron1, S. Kim2

Author affiliations

  • 1 University of Edinburgh Cancer Research Centre, Institute of Genetics and Cancer, Western General Hospita, Edinburgh/GB
  • 2 Asan Medical Center - University of Ulsan College of Medicine, Seoul/KR

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Introduction and first vote

Presenter: David Cameron

Session: Can we decrease chemotherapy in LN+ premenopausal women based on genomic tests?

Resources:

Slides

Webcast

Yes

Presenter: Janice Wing-Hang Tsang

Session: Can we decrease chemotherapy in LN+ premenopausal women based on genomic tests?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.